Hypertension and nephrology

[Therapy of isolated systolic hypertension III.]

FARSANG Csaba

OCTOBER 20, 2017

Hypertension and nephrology - 2017;21(05)

[In the elderly and very elderly (˃80 yrs), a wealth of data from large clinical trials are available, showing the necessity of treatment mostly with drug combinations - fix-combinations are preferred for increasing the adherence/persistence to therapy. Using diuretics, ACE-inhibitors/ARBs with calcium antagonists, and in special cases diuretics and beta blockers are also suggested by recent European guidelines (ESH, HSH). The target is <140 mmHg, but in octogenarians <150 mmHg. Some studies are pressing for even lower SBP (to around 120 mm Hg), but it seems to be wise to balance advantages/disadvantages, so the optimal SBP may be around 130 mmHg.]

COMMENTS

0 comments

Further articles in this publication

Hypertension and nephrology

[A Letter to Our Readers]

KÉKES Ede

Hypertension and nephrology

[Thoughts about the Jubilee Congress of the Hungarian Society for Hypertension and a Message to the Guardians...]

KISS István

Hypertension and nephrology

[A Letter to our Colleagues]

JÁRAI Zoltán

Hypertension and nephrology

[New results on the pathomechanism of antibody-mediated renal allograft rejection]

MEZÔ Blanka, ANDREAS Heilos, RUSAI Krisztina, PROHÁSZKA Zoltán

[Antibody mediated rejection (ABMR) is a severe clinical problem which is the major immunological cause of kidney transplant failure and may develop slowly months or years after transplantation. According to current knowledge, late ABMR is classically caused by the development of donor specific antibodies (DSA) and the complement system is believed to contribute to tissue damage. The detection of ABMR has been facilitated by improved techniques and new test, resulting in changes of the diagnostic criteria from time to time. The clinical interpretation of DSAs is still not clear however the complement binding ability could help to judge their relevance. In this review we discuss the new results on the pathomechanism and current diagnostic guideline of ABMR. Identification and treatment of ABMR before onset of clinical symptoms is still a big challenge but may lead to a significantly better outcome. In our study we are investigating the role of the complement system including quantitative and genetic testing of several complement proteins that can serve as a diagnostic/prognostic marker of the disease.]

Hypertension and nephrology

[Healthy Living Issues that Need to be “Clarified” – Results from the PURE Study]

VÁLYI Péter

All articles in the issue

Related contents

Clinical Neuroscience

COVID-19 and post-poliomyelitis syndrome: coincidence?

AGIRCAN Dilek , ETHEMOGLU Ozlem , GESOGLU-DEMIR Tülin

Although severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus, many central and peripheral nervous system manifestations associated with coronavirus disease-19 (COVID-19) infection have been reported. Beyond the neurologic manifestations, we may still have much to learn about the neuropathologic mechanism of SARS-CoV-2 infection. Here we report a case of post-poliomyelitis syndrome (PPS) related to COVID-19 and attempt to predict the possible pathophysiologic mechanism behind this association.

Lege Artis Medicinae

[Hypertension, COPD and COVID-19. Focus on antihypertensive therapy]

FARSANG Csaba

[Chronic obstructive pulmonary disease is a very common comorbidity of hypertension and it is often unrecognised by physicians. The factors involved in the pathomechanism of both diseases should be realised when choosing treatment. Among factors, hypoxia, increased tone of sympathetic nervous system and activation of renin-angiotensin-aldosterone system should primarily be considered. Vascular wall damage and endothelial dysfunction has an important role in both conditions. The goals of treatment are elimination of risk factors, optimizing the blood pressure, the consequential prevention of cardio-cerebrovascular, renal and pulmonary damage; finally prolonging the patients’ life and improving their quality of life as well. Both hypertension and COPD significantly worsen the condition of COVID-19 patients since they increase the severity of the disease and the rate of in-patients’ and their mortality. In the treatment of hypertension among COPD and COVID-19 patients there must be emphasized the medication inhibiting of renin-angiotensin-aldosterone system, such as angiotensin-converting en­zyme inhibitors or angiotensin-II AT1 re­cep­tor antagonists. Special attention concerned the beneficial effect of mineralocorticoid receptor antagonist spironolactone. Other antihypertensive drugs (calcium channel blockers, thiazide-like diu­retics, high selectivity β1 receptor antagonists) may supplement the treatment if necessary. Long-acting β2 receptor agonists, muscarinic receptor antagonists and inhalation corticosteroids may be administered in double or triple combination also in hypertension and COPD as well. It is important to note, that statin therapy and also vitamin D3 improve the condition of COVID-19 patients.]

Clinical Neuroscience

[Epidemiology, cost and economic impact of cerebral palsy in Hungary]

FEJES Melinda, VARGA Beatrix, HOLLÓDY Katalin

[Objective - The purpose of our communication was to determine the total cost of cerebral paretic patients in Hungary between 0 and 18 years and to assess their impact on the national budget. Methods - Based on the data of Borsod county we calculated the CP characteristics. The cost of CP was determined by routine care of individuals. Lost Parental Income and Tax were calculated on the basis of average earnings. The ratio of GDP, Health and Social Budget and Health Budget to CP is based on CP annual average cost and frequency. We have developed a repeatable computational model. Results - Of the risk groups, premature birth (30.97%), low birth weight (29.64%), perinatal asphyxia (19.47%) were the most common. Source is unknown of 37.61% of the cases. CP prevalence was 2.1‰. The two-sided (59.7%) and the one-sided (19.0%) spastic pareses dominated. The most serious form is the two-sided spastic paresis (42.5% GMFCS 3-5 degrees). Epilepsy was 22.0%, incontinence was 27%, mental involvement was 46%. Care for one child up to 18 years of age costs an average of 73 million HUF (€ 251,724). The lost family income was 27.36 million HUF (€ 94,345), and lost tax and health care contributions were 14.46 million HUF (€ 49,862). Additionally, 0.525% of the GDP, 0.88% of the full health and social budget and 1.83% of direct medical costs were spent for CP families. Conclusion - The cost of CP disease is significant. Costs can be reduced by improving primary prevention. From the perspective of the family and government, it is better to care for families so they can take care of their disabled children.]

Clinical Neuroscience

[Post-operative management of primary glioblastoma multiforme in patients over 60 years of age]

DARÓCZI Borbála, SZÁNTÓ Erika, TÓTH Judit, BARZÓ Pál, BOGNÁR László, BAKÓ Gyula, SZÁNTÓ János, MÓZES Petra, HIDEGHÉTY Katalin

[Background and purpose - Optimal treatment for elderly patients with glioblastoma multiforme is not well defined. We evaluated the efficacy of post-operative radiotherapy with or without concomitant and/or adjuvant temozolomide in patients aged ≥60 years to assess survival and identify prognostic factors of survival. Methods - A retrospective analysis of overall survival and progression-free survival in patients with newly diagnosed glioblastoma multiforme aged ≥60 years treated with postoperative radiotherapy with or without temozolomide chemotherapy was conducted at our institutions. Prognostic factors were determined by univariate and multivariate analyses. Results - Of 75 study participants (54.7% male; median age at first diagnosis, 65.1 years), 29 (38.7%) underwent gross total resection, whereas others underwent partial resection or biopsy only. All but 1 patient received radiotherapy. Twenty patients received concomitant temozolomide only. Adjuvant temozolomide (1-50 cycles) was administered in 42 patients; 16 received ≥6 cycles. Median overall survival was 10.3 months. One- and 2-year overall survival rates were 42.6% and 6.7%, respectively. Median progression-free survival was 4.1 months. Radiochemotherapy was generally well tolerated. Median overall survival was 15.3 and 29.6 months for patients who received 6-12 cycles and >12 cycles of adjuvant temozolomide, respectively. There were no significant differences in overall survival between age groups (60-64, 65-69, and ≥70 years). Adjuvant temozolomide, Karnofsky performance status ≥70, and additional surgery after progression were significant prognostic factors of longer overall survival (p<0.05). Conclusions: Radiochemotherapy, including ≥6 cycles of adjuvant temozolomide, was safe and prolonged survival of glioblastoma patients aged ≥60 years. Aggressive therapy should not be withheld from patients aged ≥60 years with good performance status because of age.]

Hypertension and nephrology

[Cilostazol improves quality of life and lower limb functional capacity in lower extremity arterial disease regardless of age and gender – new results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study]

FARKAS Katalin, KOLOSSVÁRY Endre , JÁRAI Zoltán

[Intermittent claudication has a significant negative impact on the patients’ quality of life. Revascularization procedures and noninvasive medical therapie scan improve walking capacity. Cilostazol has IA recommendation for the treatment of intermittent claudication (IC). The aim of this study was to evaluate the effect of three-month cilostazol treatment on the health related quality of life and on the lower limb functional capacity in women (F) and men (M), in patients under 65 years of age (Y) and among patients 65 years of age or older (O) with intermittent claudication in the clinical practice. The study was a multicenter, non-interventional trial, 812 lower extremity arterial disease (LEAD) patients (Fontaine II stage, mean age: 67.17 years, male/female: 58.25/41.75%, 506 patients aged ≥65 years) were enrolled, who received cilostazol (50 or 100 mg b.i.d.) for three months. Quality of life was evaluated with the EQ- 5D-3L questionnaire, functional capacity with the WELCH questionnaire. Walking distances, ankle-brachial index were measured at baseline and after 3-month. Upon conclusion of the study, the EQ-5D index improved (baseline: F [female] –0.49±0.23, M (male –0.44±0.22, Y (age <65 years) –0.45±0.21, O (age ≥65 years) –0.47±0.23; 3rd month: –0.27±0.18, –0.25±0.18, –0.25±0.18, –0.26±0.18; respectively, p<0.0001) and there was a significant increase in the WELCH score as well (baseline: F 18±13, M 20±14, Y 21±14, O 18±13; 3rd month: 31±18, 32±18, 32±19, 31±17; respectively, p<0.0001). Both pain-free and maximal walking distance increased: F 60.94%, (median: +50.26%), 49.57%, (median: + 42.86%), M 50.22%, (median: +50%), 37.7%, (median: + 33,33 %), Y 54,35 %, (median: + 56,2%), 36.78%, (median: +42.86%), O 54.62%, (median: +50%), 46.29% (median: +33.33%); respectively (p<0.001). Three months of cilostazol treatment improved quality of life and lower limb functional capacity in claudicant patients regardless of age and gender. The WELCH questionnaire is a useful tool in clinical practice for the evaluation of intermittent claudication treatment.]